SCHEMBL17712366

SCHEMBL17712366

Cc1c(C(=O)N2CCCC23CN([C@H](C(N)=O)[C@@H](C)O)C3=O)nnn1Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.49
GRIN2C Q14957 1/20 0.49
KLKB1 P03952 1/20 0.37
HPGD P15428 1/20 0.35
CYP19A1 P11511 4/20 0.35
CYP1A2 P05177 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 1/20 0.34
CYP2D6 P10635 1/20 0.34
DRD2 P14416 4/20 0.33
DRD4 P21917 4/20 0.33
DRD3 P35462 4/20 0.33
HTR2A P28223 3/20 0.33
KDM4E B2RXH2 3/20 0.33
MEN1 O00255 1/20 0.33
GLA P06280 1/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
PFKFB3 Q16875 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19229626 1.00 GRIN2B (0.49) GRIN2BGRIN2CKLKB1HPGDCYP19A1
SCHEMBL20485072 1.00 GRIN2B (0.49) GRIN2BGRIN2CKLKB1HPGDCYP19A1
SCHEMBL23709405 0.87 GRIN2B (0.38) GRIN2BGRIN2CKLKB1HPGDCYP19A1
SCHEMBL21467087 0.84 CYP19A1 (0.39) KLKB1HPGDCYP19A1CYP1A2SMN1; SMN2
SCHEMBL18556507 0.82 GRIN2B (0.51) GRIN2BGRIN2CKLKB1HPGDCYP1A2
SCHEMBL15936941 0.78 HPGD (0.38) KLKB1HPGDCYP19A1CYP1A2SMN1; SMN2
SCHEMBL17351843 0.76 KLKB1 (0.34) KLKB1CYP19A1CYP1A2SMN1; SMN2ALDH1A1
SCHEMBL19134496 0.76 KLKB1 (0.34) KLKB1CYP19A1CYP1A2SMN1; SMN2ALDH1A1
SCHEMBL17351846 0.76 KLKB1 (0.34) KLKB1CYP19A1CYP1A2SMN1; SMN2ALDH1A1
SCHEMBL19853466 0.74 GRIN2B (0.47) GRIN2BGRIN2CALDH1A1CYP2D6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186392-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) 2025-06-12 US disclosed
US-12167998-B2 Spiro-lactam NMDA receptor modulators and uses thereof TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) 2024-12-17 US disclosed
EP-3514158-B1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2022-10-12 EP disclosed
US-20220151992-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2022-05-19 US disclosed
US-20220151992-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2022-05-19 US disclosed
US-11077094-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2021-08-03 US disclosed
US-20200206189-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2020-07-02 US disclosed
US-10441571-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2019-10-15 US disclosed
US-10441571-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2019-10-15 US disclosed
US-10441572-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2019-10-15 US disclosed
US-20160368926-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF Aptinyx Incorporated (US) 2016-12-22 US disclosed
US-9512134-B2 Spiro-lactam NMDA receptor modulators and uses thereof Aptinyx, Inc. (US) 2016-12-06 US disclosed
US-9512134-B2 Spiro-lactam NMDA receptor modulators and uses thereof Aptinyx, Inc. (US) 2016-12-06 US disclosed
US-9504670-B2 Spiro-lactam NMDA receptor modulators and uses thereof Aptinyx, Inc. (US) 2016-11-29 US disclosed
US-9504670-B2 Spiro-lactam NMDA receptor modulators and uses thereof Aptinyx, Inc. (US) 2016-11-29 US disclosed
US-20160289240-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2016-10-06 US disclosed
US-20160289240-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2016-10-06 US disclosed
US-20160122359-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2016-05-05 US disclosed
US-20160122359-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2016-05-05 US disclosed
US-20160122359-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2016-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160289240-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885KLKB1 1418/4885
US-20250186392-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885KLKB1 1418/4885
US-12167998-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885KLKB1 1418/4885
US-20160368926-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885KLKB1 1418/4885
US-20220151992-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885KLKB1 1418/4885
US-10441571-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885KLKB1 1418/4885
US-20200206189-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885KLKB1 1418/4885
US-10441572-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885KLKB1 1418/4885
US-20160122359-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN2B GRIN2B 3/4885GRIN2C 6/4885KLKB1 2726/4885
US-11077094-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885KLKB1 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.